Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus standard of care in previously untreated advanced non-clear cell renal cell carcinoma
2016-000706-12Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing Nivolumab + ipilimumab with Standard of care (2 arms). Primary endpoint: Overall survival rate at 12 months. Started Nov 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2016-000706-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000706-12.